Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Benjamin

Showing results (891-900 of 920) with videos related to

Pageof 92
Sort By:
Journal of the National Cancer Institute|September 1, 2016
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing SarcomaSalah-Eddine Lamhamedi-Cherradi, Brian A Menegaz, Vandhana Ramamoorthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2018
Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient SurvivalVivek Subbiah, Salah-Eddine Lamhamedi-Cherradi, Branko Cuglievan, et al.
Cancer|August 28, 2024
Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomesAndrew J Bishop, Devarati Mitra, Ahsan Farooqi, et al.
Cancer|July 6, 2022
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort studyVinod Ravi, Aparna Subramaniam, Jing Zheng, et al.
Cancer Research|September 3, 2004
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumorsLei L Chen, Jonathan C Trent, Elsie F Wu, et al.
Melanoma Research|May 12, 2009
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrenceKevin B Kim, Sewa S Legha, Rene Gonzalez, et al.
The Lancet. Oncology|November 7, 2022
Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trialB Ashleigh Guadagnolo, Roland L Bassett, Devarati Mitra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 29, 2010
Bone cancerJ Sybil Biermann, Douglas R Adkins, Robert S Benjamin, et al.
Nature Communications|February 22, 2020
Immuno-genomic landscape of osteosarcomaChia-Chin Wu, Hannah C Beird, J Andrew Livingston, et al.
Cancer Medicine|March 13, 2021
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literatureAnna M Frezza, Vinod Ravi, Salvatore Lo Vullo, et al.
Pageof 92

Showing results (891-900 of 920) with videos related to

Sort By:
Pageof 92
Journal of the National Cancer Institute|September 1, 2016
IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing SarcomaSalah-Eddine Lamhamedi-Cherradi, Brian A Menegaz, Vandhana Ramamoorthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 7, 2018
Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient SurvivalVivek Subbiah, Salah-Eddine Lamhamedi-Cherradi, Branko Cuglievan, et al.
Cancer|August 28, 2024
Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomesAndrew J Bishop, Devarati Mitra, Ahsan Farooqi, et al.
Cancer|July 6, 2022
Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort studyVinod Ravi, Aparna Subramaniam, Jing Zheng, et al.
Cancer Research|September 3, 2004
A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumorsLei L Chen, Jonathan C Trent, Elsie F Wu, et al.
Melanoma Research|May 12, 2009
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrenceKevin B Kim, Sewa S Legha, Rene Gonzalez, et al.
The Lancet. Oncology|November 7, 2022
Hypofractionated, 3-week, preoperative radiotherapy for patients with soft tissue sarcomas (HYPORT-STS): a single-centre, open-label, single-arm, phase 2 trialB Ashleigh Guadagnolo, Roland L Bassett, Devarati Mitra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 29, 2010
Bone cancerJ Sybil Biermann, Douglas R Adkins, Robert S Benjamin, et al.
Nature Communications|February 22, 2020
Immuno-genomic landscape of osteosarcomaChia-Chin Wu, Hannah C Beird, J Andrew Livingston, et al.
Cancer Medicine|March 13, 2021
Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literatureAnna M Frezza, Vinod Ravi, Salvatore Lo Vullo, et al.
Pageof 92